Global Head and Neck Cancer Market

Report ID : 1217 | Published : 2022-03-25 | Pages: | Format:

According to the study published in NCBI (2014), head and neck cancer (HNC) is the sixth most common cancer worldwide, with an estimated 630,000 new cases every year. Specifically, this type of cancer includes tumors of the oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity. Tobacco and alcohol consumption is strongly associated with head and neck cancer.

Multiple factors that drive the head and neck cancer market include the increasing combination therapies for the management of head & neck cancer, rising prevalence of head and neck cancer, increasing adoption of advanced medical technologies, reduction in medical errors in cancer care, various government initiatives for various cancer therapy developments, and increasing awareness among people regarding the advanced cancer treatments. In addition, risk factors such as growth in cigarette smoking, alcohol intake & tobacco use are expected to fuel the market growth.

However, the high cost of treatments, the side effects of available therapies, and the lack of health coverage act as major restraints of this market.

The head and neck cancer market has been segmented on the basis of product and region. The products segment comprises of cytotoxic agents [Antimetabolites (Abitrexate/ Mexate/ Folex (methotrexate), hydrea (hydroxyurea), antitubulins, taxotere (docetaxel), others (Platinum Agents, Fluoropyrimidines), Platinol (cisplatin), 5-fluorouracil (5-FU)], EGFR Inhibitors [Erbitux (cetuximab), Vectibi (panitumumab), Theracim/Theraloc (nimotuzumab)], EGFR Inhibitors (TKIs) [Tarceva (erlotinib), Iressa (gefitinib), Tykerb/Tyverb (lapatinib)], PD1 Inhibitors [Keytruda (pembrolizumab), Opdivo (nivolumab)], Pipeline Drugs [EGFR Inhibitors (mAbs) (Vectibix (panitumumab)), PDL1 Inhibitors (Imfinzi (durvalumab), Bavencio (avelumab)), CTLA4 Inhibitors (Yervoy (ipilimumab), Tremelimumab)]. At regional level, the head and neck cancer market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The North American region is projected to hold the major market share in 2020, followed by Europe, Asia-Pacific, and Rest-of-the-World.

The major key players operating in the head and neck cancer market are Advaxis, Inc. (US), Amgen, Inc. (US), AstraZeneca plc (UK), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.) (Japan), Cel-Sci Corporation (US), Five Prime Therapeutics, Inc. (US), GlaxoSmithKline plc (UK), Incyte Corporation (US), IRX Therapeutics, Inc. (US), MacroGenics, Inc. (US), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer, Inc., Roche Holdings AG (Genentech) (Switzerland), Viracta Therapeutics   (US) among others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Cell Head and Neck Cancer Market Snapshot

Chapter 4. Global Cell Head and Neck Cancer Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Clinical Trial/Pipeline Analysis

4.9. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 3: By Products Estimates & Trend Analysis

5.1. By Products & Market Share, 2020& 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Products:

5.2.1. Cytotoxic Agents

5.2.1.1.  Antimetabolites

5.2.1.1.1.  Abitrexate/ Mexate/ Folex (methotrexate)

5.2.1.1.2.  Hydrea (hydroxyurea)

5.2.1.2.  Antitubulins

5.2.1.2.1.  Taxotere (docetaxel)

5.2.1.3.  Others (Platinum Agents, Fluoropyrimidines)

5.2.1.3.1.  Platinol (cisplatin)

5.2.1.3.2.  5-fluorouracil (5-FU)

5.2.2. EGFR Inhibitors (mAbs)

5.2.2.1.  Erbitux (cetuximab)

5.2.2.2.  Vectibix (panitumumab)

5.2.2.3.  Theracim/Theraloc (nimotuzumab)

5.2.3. EGFR Inhibitors (TKIs)

5.2.3.1.  Tarceva (erlotinib)

5.2.3.1.1.  Iressa (gefitinib)

5.2.3.2.  Tykerb/Tyverb (lapatinib)

5.2.4. PD1 Inhibitors

5.2.4.1.  Keytruda (pembrolizumab)

5.2.4.2.  Opdivo (nivolumab)

5.2.5. Pipeline Drugs (Late-stage)

5.2.5.1.  EGFR Inhibitors (mAbs)

5.2.5.1.1.  Vectibix (panitumumab)

5.2.5.2.  PDL1 Inhibitors

5.2.5.2.1.  Imfinzi (durvalumab)

5.2.5.2.2.  Bavencio (avelumab)

5.2.5.3.  CTLA4 Inhibitors

5.2.5.3.1.  Yervoy (ipilimumab)

5.2.5.3.2.  Tremelimumab

Chapter 6. Cell Head and Neck Cancer Market Segmentation 5: Regional Estimates & Trend Analysis

6.1. North America

6.1.1. North America Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts By Products, 2020-2030

6.1.2. North America Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

6.2. Europe

6.2.1. Europe Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2020-2030

6.2.2. Europe Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2020-2030

6.3. Asia Pacific

6.3.1. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2020-2030

6.3.2. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts by Types, 2020-2030

6.3.3. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2020-2030

6.4. Latin America

6.4.1. Latin America Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2020-2030

6.4.2. Latin America Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2020-2030

6.5. Middle East & Africa

6.5.1. Middle East & Africa Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2020-2030

6.5.2. Middle East & Africa Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2020-2030

Chapter 7. Competitive Landscape

7.1. Major Mergers and Acquisitions/Strategic Alliances

7.2. Company Profiles

7.2.1. Advaxis, Inc.

7.2.2. Amgen, Inc.

7.2.3. AstraZeneca plc

7.2.4. Boehringer Ingelheim GmbH

7.2.5. Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.)

7.2.6. Cel-Sci Corporation

7.2.7. Five Prime Therapeutics, Inc.

7.2.8. GlaxoSmithKline plc

7.2.9. Incyte Corporation

7.2.10. IRX Therapeutics, Inc.

7.2.11. MacroGenics, Inc.

7.2.12. Merck KGaA

7.2.13. Novartis AG

7.2.14. Pfizer, Inc.

7.2.15. Roche Holdings AG (Genentech)

7.2.16. Viracta Therapeutics

7.2.17. Other Prominent Players

Global Head and Neck Cancer Market, by Products, 2020-2030 (Value US$ Mn)

  • Cytotoxic Agents
  • Antimetabolites
  • Abitrexate/ Mexate/ Folex (methotrexate)
  • Hydrea (hydroxyurea)
  • Antitubulins
  • Taxotere (docetaxel)
  • Others (Platinum Agents, Fluoropyrimidines)
  • Platinol (cisplatin)
  • 5-fluorouracil (5-FU)
  • EGFR Inhibitors (mAbs)
  • Erbitux (cetuximab)
  • Vectibix (panitumumab)
  • Theracim/Theraloc (nimotuzumab)
  • EGFR Inhibitors (TKIs)
  • Tarceva (erlotinib)
  • Iressa (gefitinib)
  • Tykerb/Tyverb (lapatinib)
  • PD1 Inhibitors
  • Keytruda (pembrolizumab)
  • Opdivo (nivolumab)
  • Pipeline Drugs (Late-stage)
  • EGFR Inhibitors (mAbs)
  • Vectibix (panitumumab)
  • PDL1 Inhibitors
  • Imfinzi (durvalumab)
  • Bavencio (avelumab)
  • CTLA4 Inhibitors
  • Yervoy (ipilimumab)
  • Tremelimumab 

Global Head And Neck Cancer Market, by Region, 2020-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

\North America Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific  Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa, rest of Middle East & Africa

Competitive Landscape

  • Advaxis, Inc.
  • Amgen, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.)
  • Cel-Sci Corporation
  • Five Prime Therapeutics, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • IRX Therapeutics, Inc.
  • MacroGenics, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Roche Holdings AG (Genentech)
  • Viracta Therapeutics

Other Prominent Players

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Head and Neck Cancer Market?

Head and Neck Cancer Market worth $ 9.07 Billion by 2030

CAGR of 16.2% during the forecast period 2022-2030

Our Clients